Scynexis Inc financial data

Symbol
SCYX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1 Evertrust Plaza, 13 Th Floor, Jersey City, NJ
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 341 % -25.9%
Quick Ratio 25.8 % +354%
Debt-to-equity 67.6 % -43.8%
Return On Equity -34.3 % -129%
Return On Assets -20.5 % -138%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39M shares +3.25%
Common Stock, Shares, Outstanding 38M shares +2.06%
Weighted Average Number of Shares Outstanding, Basic 48.5M shares +1.38%
Weighted Average Number of Shares Outstanding, Diluted 48.5M shares +0.25%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.75M USD
Research and Development Expense 26.4M USD -14.6%
Operating Income (Loss) -37.1M USD -151%
Nonoperating Income (Expense) 16M USD +0.47%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.1M USD -131%
Income Tax Expense (Benefit) 151K USD +9.42%
Net Income (Loss) Attributable to Parent -21.3M USD -132%
Earnings Per Share, Basic -0.44 USD/shares -131%
Earnings Per Share, Diluted -0.44 USD/shares -132%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.1M USD -52.9%
Cash, Cash Equivalents, and Short-term Investments 75.1M USD -23.4%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 0 USD -100%
Other Assets, Current 1.23M USD -74.8%
Assets, Current 72.2M USD -29.3%
Operating Lease, Right-of-Use Asset 2.09M USD -11.6%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 90.6M USD -29.4%
Accounts Payable, Current 4.57M USD -36.1%
Accrued Liabilities, Current 3.79M USD -49.4%
Liabilities, Current 24.1M USD +47.8%
Operating Lease, Liability, Noncurrent 2.18M USD -15.7%
Liabilities 35.6M USD -35.9%
Retained Earnings (Accumulated Deficit) -377M USD -5.99%
Stockholders' Equity Attributable to Parent 55.1M USD -24.5%
Liabilities and Equity 90.6M USD -29.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.01M USD +78.8%
Net Cash Provided by (Used in) Financing Activities 22K USD -99.7%
Net Cash Provided by (Used in) Investing Activities 5.45M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 38M shares +2.06%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.6M USD -52%
Interest Paid, Excluding Capitalized Interest, Operating Activities 420K USD -74.7%
Deferred Tax Assets, Valuation Allowance 68.6M USD +13.1%
Deferred Tax Assets, Gross 68.6M USD +13.1%
Operating Lease, Liability 2.58M USD -11.6%
Lessee, Operating Lease, Liability, to be Paid 3.53M USD -17.1%
Operating Lease, Liability, Current 407K USD +19.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 759K USD +2.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 744K USD +1.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 951K USD -29.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 774K USD +1.98%
Deferred Tax Assets, Operating Loss Carryforwards 48.7M USD +4.84%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 358K USD -0.83%
Lessee, Operating Lease, Liability, to be Paid, Year Four 790K USD +2.07%
Operating Lease, Payments 730K USD +2.1%
Additional Paid in Capital 432M USD +0.8%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 3.35M USD +27.5%
Interest Expense 836K USD -85.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%